Smad3 as a mediator of the fibrotic response

International Journal of Experimental Pathology

Volumn 85, Issue 2, 2004, Pages 47-64

  Flanders, Kathleen C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Fibrosis; Halofuginone; Smad3; Smad7; TGF ; Wound healing

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ACTIVIN; ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CALCITRIOL; CARBON TETRACHLORIDE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; FLUOROURACIL; HALOFUGINONE; IMIDAZOLE DERIVATIVE; INSULIN; INTERLEUKIN 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OSTEOGENIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN INHIBITOR; PROTEIN SERINE THREONINE KINASE; SB 505124; SERASPENIDE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER RADIOTHERAPY; CARDIOVASCULAR SYSTEM; CELL ACTIVATION; CELL DIFFERENTIATION; CHEMOTAXIS; CHRONIC HEPATITIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE MODEL; DRUG MECHANISM; DRUG POTENCY; EXTRACELLULAR MATRIX; EYE; EYE INJURY; FIBROBLAST; FIBROGENESIS; FIBROSING ALVEOLITIS; FIBROSIS; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; GLOMERULOSCLEROSIS; HEPATITIS C; HUMAN; HYPERTENSION; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINAL FIBROSIS; KELOID; KIDNEY; KIDNEY FIBROSIS; KNOCKOUT MOUSE; LIVER; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG FIBROSIS; MEDIATOR; MESENCHYME CELL; MOUSE MUTANT; NONHUMAN; NULL ALLELE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STRUCTURE; RADIATION INJURY; RADIOSENSITIVITY; REGULATORY MECHANISM; REVIEW; SCAR; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; STREPTOZOCIN DIABETES; TRANSCRIPTION REGULATION; URETER OBSTRUCTION; VIRAL GENE THERAPY; VITREORETINOPATHY; WOUND HEALING;

ANIMALS; CHOLECALCIFEROL; CYTOKINES; DNA-BINDING PROTEINS; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 2542609844     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0959-9673.2004.00377.x     Document Type: Review

References (105)

1. Aschenbrenner J.K., Sollinger H.W., Becker B.N., Hullett D.A. (2001) 1,25-(OH(2)D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J. Surg. Res. 100, 171-175.
2. Ashcroft G.S., Yang X., Glick A.B. et al. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol. 1, 260-266.
3. Attisano L. & Tuen Lee-Hoeflich S. (2001) The smads. Genome Biol. 2, reviews 3010.1-3010.8.
4. Barcellos-Hoff M.H., Derynck R., Tsang M.L., Weatherbee J.A. (1994) Transforming growth factor-beta activation in irradiated murine mammary gland. J. Clin. Invest. 93, 892-899.
5. Border W.A. & Noble N.A. (1994) Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292.
6. Bruck R., Genina O., Aeed H., Alexiev R., Nagler A., Avni Y., Pines M. (2001) Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33, 379-386.
7. Byfield S.A.D., Major C., Laping N.J., Roberts A.B. (2004) SB-505124 is a selective inhibitor of TGF-β type I receptors ALK4, ALK5 and ALK7. Mol. Pharmacol. 65, 744-752.
8. Chen R., Huang C., Morinelli T.A., Trojanowska M., Paul R.V. (2002) Blockade of the effects of TGF-beta1 on mesangial cells by overexpression of Smad7. J. Am. Soc. Nephrol. 13, 887-893.
9. Chen S.J., Yuan W., Lo S., Trojanowska M., Varga J. (2000) Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. J. Cell Physiol. 183, 381-392.
10. Chin G.S., Liu W., Peled Z. et al. (2001) Differential expression of transforming growth factor-beta receptors I and II and activation of smad 3 in keloid fibroblasts. Plast. Reconstr. Surg. 108, 423-429.
11. Datta P.K., Blake M.C., Moses H.L. (2000) Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta -induced physical and functional interactions between smads and Sp1. J. Biol. Chem. 275, 40014-40019.
12. Datto M.B., Frederick J.P., Pan L., Borton A.J., Zhuang Y., Wang X.F. (1999) Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell Biol. 19, 2495-2504.
13. Dennler S., Itoh S., Vivien D., Ten Dijke P., Huet S., Gauthier J.M. (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17, 3091-3100.
14. Denton C.P. & Abraham D.J. (2001) Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr. Opin. Rheumatol. 13, 505-511.
15. Derynck R. & Zhang Y.E. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584.
16. Dong C., Zhu S., Wang T. et al. (2002) Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl. Acad. Sci. USA. 99, 3908-3913.
17. Dooley S., Hamzavi J., Breitkopf K. et al. (2003) Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125, 178-191.
18. Feinberg M.W., Jain M.K., Werner F. et al. (2000) Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J. Biol. Chem. 275, 25766-25773.
19. Felici A., Wurthner J.U., Parks W.T. et al. (2003) TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling. EMBO J. 22, 4465-4477.
20. Flanders K.C. & Burmester J.K. (2003) Medical applications of transforming growth factor-β. Clin. Med. Res. 1, 13-20.
21. Flanders K.C., Major C.D., Arabshahi A. et al. (2003) Interference with transforming growth factor-beta/ Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. Am. J. Pathol. 163, 2247-2257.
22. Flanders K.C., Sullivan C.D., Fujii M. et al. (2002) Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am. J. Pathol. 160, 1057-1068.
23. Fu M., Zhang J., Zhu X. et al. (2001) Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J. Biol. Chem. 276, 45888-45894.
24. Fujimoto M., Maezawa Y., Yokote K. et al. (2003) Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 305, 1002-1007.
25. Furukawa F., Matsuzaki K., Mori S. et al. (2003) p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38, 879-889.
26. Ghosh A.K., Yuan W., Mori Y., Chen S., Varga J. (2001) Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J. Biol. Chem. 276, 11041-11048.
27. Ghosh A.K., Yuan W., Mori Y., Varga J. (2000) Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Clin. Exp. Nephrol. 19, 3546-3555.
28. Goumans M.J., Lebrin F., Valdimarsdottir G. (2003) Controlling the angiogenic switch: a balance between two distinct TGF-β receptor signaling pathways. Trends Cardiovasc. Med. 13, 301-307.
29. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., Ten Dijke P. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 21, 1743-1753.
30. Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. (2002) Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 7, d793-807.
31. Hall M.C., Young D.A., Waters J.G. et al. (2003) The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J. Biol. Chem. 278, 10304-10313.
32. Hao J., Ju H., Zhao S. et al. (1999) Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J. Mol. Cell Cardiol. 31, 667-678.
33. Hauer-Jensen M., Richter K.K., Wang J., Abe E., Sung C.C., Hardin J.W. (1998) Changes in transforming growth factor beta1 gene expression and immunoreactivity levels during development of chronic radiation enteropathy. Radiat. Res. 150, 673-680.
34. Hayashida T., Decaestecker M., Schnaper H.W. (2003) Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 17, 1576-1578.
35. Hayes S., Chawla A., Corvera S. (2002) TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J. Cell Biol. 158, 1239-1249.
36. Higashi K., Inagaki Y., Fujimori K., Nakao A., Kaneko H., Nakatsuka I. (2003) Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. J. Biol. Chem. 278, 43470-43479.
37. Holmes A., Abraham D.J., Sa S., Shiwen X., Black C.M., Leask A. (2001) CTGF and smads, maintenance of scleroderma phenotype is independent of smad signaling. J. Biol. Chem. 276, 10594-10601.
38. Hong S.W., Isono M., Chen S., Iglesias-De La Cruz M.C., Han D.C., Ziyadeh F.N. (2001) Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am. J. Pathol. 158, 1653-1663.
39. Hu Y., Chuang J.Z., Xu K., McGraw T.G., Sung C.H. (2002) SARA, a FYVE domain protein, affects Rab5-mediated endocytosis. J. Cell Sci. 115, 4755-4763.
40. Huang M., Sharma S., Zhu L.X. et al. (2002) IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J. Clin. Invest. 109, 931-937.
41. Inagaki Y., Mamura M., Kanamaru Y. et al. (2001) Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J. Cell Physiol. 187, 117-123.
42. Inagaki Y., Nemoto T., Kushida M. et al. (2003) Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38, 890-899.
43. Inagaki Y., Nemoto T., Nakao A. et al. (2001) Interaction between GC box binding factors and Smad proteins modulates cell lineage-specific alpha 2(I) collagen gene transcription. J. Biol. Chem. 276, 16573-16579.
44. Isono M., Chen S., Won H.S., Carmen Iglesias-De La Cruz, Ziyadeh F. (2002) Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem. Biophys. Res. Commun. 296, 1356-1365.
45. Kanasaki K., Koya D., Sugimoto T., Isono M., Kashiwagi A., Haneda M. (2003) N-Acetyl-Seryl-Aspartyl-Lysyl-Proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J. Am. Soc. Nephrol. 14, 863-872.
46. Kelley T.J., Elmer H.L., Corey D.A. (2001) Reduced Smad3 protein expression and altered transforming growth factor-beta1-mediated signaling in cystic fibrosis epithelial cells. Am. J. Respir. Cell Mol. Biol. 25, 732-738.
47. Kim J.H., Kim B.K., Moon K.C., Hong H.K., Lee H.S. (2003) Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 64, 1715-1721.
48. Kingsley D.M. (1994) The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8, 133-146.
49. Kon A., Vindevoghel L., Kouba D.J., Fujimura Y., Uitto J., Mauviel A. (1999) Cooperation between SMAD and NF-kappaB in growth factor regulated type VII collagen gene expression. Clin. Exp. Nephrol. 18, 1837-1844.
50. Kretschmer A., Moepert K., Dames S., Sternberger M., Kaufmann J., Klippel A. (2003) Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. Clin. Exp. Nephrol. 22, 6748-6763.
51. Lan H.Y., Mu W., Tomita N. et al. (2003) Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J. Am. Soc. Nephrol. 14, 1535-1548.
52. Laping N.J., Grygielko E., Mathur A. et al. (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol. Pharmacol. 62, 58-64.
53. Letterio J.J & Roberts A.B. (1996) Transforming growth factor-beta1-deficient mice: identification of isoform-specific activities in vivo. J. Leukoc. Biol. 59, 769-774.
54. Li J.H., Huang X.R., Zhu H.J., Johnson R., Lan H.Y. (2003) Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 63, 2010-2019.
55. Liu X., Wen F.Q., Kobayashi T. et al. (2003) Smad3 mediates the TGF-beta-induced contraction of type I collagen gels by mouse embryo fibroblasts. Cell Motil. Cytoskeleton 54, 248-253.
56. Lutz M. & Knaus P. (2002) Integration of the TGF-beta pathway into the cellular signalling network. Cell Signal. 14, 977-988.
57. Massague J. (1998) TGF-beta signal transduction. Annu. Rev. Biochem. 67, 753-791.
58. McGaha T.L., Phelps R.G., Spiera H., Bona C. (2002) Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 118, 461-470.
59. Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., MacDonald T.T. (2001) Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108, 601-609.
60. Mori T., Kawara S., Shinozaki M. et al. (1999) Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J. Cell. Physiol. 181, 153-159.
61. Moustakas A., Souchelnytskyi S., Heldin C.H. (2001) Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114, 4359-4369.
62. Nakao A., Fujii M., Matsumura R. et al. (1999) Transient gene transfer and expression of Smad7 prevents bleomycin- induced lung fibrosis in mice. J. Clin. Invest. 104, 5-11.
63. Nomura M. & Li E. (1998) Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 393, 786-790.
64. Ota T., Fujii M., Sugizaki T. et al. (2002) Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J. Cell Physiol. 193, 299-318.
65. Penheiter S.G., Mitchell H., Garamszegi N., Edens M., Dore J.J., Jr, Leof E.B. (2002) Internalization-dependent and -independent requirements for transforming growth factor beta receptor signaling via the Smad pathway. Mol. Cell Biol. 22, 4750-4759.
66. Piek E., Ju W.J., Heyer J. et al. (2001) Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276, 19945-19953.
67. Pines M. & Nagler A. (1998) Halofuginone: a novel antifibrotic therapy. Gen. Pharmacol. 30, 445-450.
68. Pines M., Snyder D., Yarkoni S., Nagler A. (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol. Blood Marrow Transplant. 9, 417-425.
69. Poncelet A.C. & Schnaper H.W. (2001) Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(1) collagen expression in human glomerular mesangial cells. J. Biol. Chem. 276, 6983-6992.
70. Randall K. & Coggle J.E. (1995) Expression of transforming growth factor-beta 1 in mouse skin during the acute phase of radiation damage. Int. J. Radiat. Biol. 68, 301-309.
71. Roberts A.B. & Sporn M.B. (1990) The transforming growth factors-β. In: Handbook of Experimental Pharmacology 95, pp. 419-472. (eds. A.B. Roberts & M.B. Sporn) New York: Springer-Verlag.
72. Roberts A.B. & Sporn M.B. (1996) Transforming growth factor-β. In: The Molecular and Cellular Biology of Wound Repair, pp. 275-308. (Ed. by R. A. F. Clark) New York: Plenum Press.
73. Runyan C.E., Schnaper H.W., Poncelet A.C. (2003) Smad3 and PKCdelta mediate TGF-beta1-induced collagen I expression in human mesangial cells. Am. J. Physiol. Renal Physiol. 285, F413-F422.
74. Runyan C.E., Schnaper H.W., Poncelet A.C. (2004) The PI3K-Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to TGF-beta 1. J. Biol. Chem. 279, 2632-2639.
75. Saika S., Kono-Saika S., Ohnishi Y. et al. (2004) Smad3 singaling is required for epithelial-mesenchymal transistion of lens epithelium post-injury. Am. J. Pathol. 164, 651-663.
76. Saika S., Miyamoto T., Ishida I. et al. (2002) TGFbeta-Smad signalling in postoperative human lens epithelial cells. Br. J. Ophthalmol. 86, 1428-1433.
77. Saika S., Okada Y., Miyamoto T., Ohnishi Y., Ooshima A., McAvoy J.W. (2001) Smad translocation and growth suppression in lens epithelial cells by endogenous TGFbeta2 during wound repair. Exp. Eye Res. 72, 679-686.
78. Sato M., Markiewicz M., Yamanaka M. et al. (2003a) Modulation of transforming growth factor-beta (TGF-beta) signaling by endogenous sphingolipid mediators. J. Biol. Chem. 278, 9276-9282.
79. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. (2003b) Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112, 1486-1494.
80. Schnabl B., Kweon Y.O., Frederick J.P., Wang X.F., Rippe R.A., Brenner D.A. (2001) The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34, 89-100.
81. Schnaper H.W., Hayashida T., Hubchak S.C., Poncelet A.C. (2003) TGF-beta signal transduction and mesangial cell fibrogenesis. Am. J. Physiol. Renal Physiol. 284, F243-F252.
82. Shi Y. & Massague J. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700.
83. Sumiyoshi K., Nakao A., Setoguchi Y., Okumura K., Tsuboi R., Ogawa H. (2003) Smads regulate collagen gel contraction by human dermal fibroblasts. Br. J. Dermatol. 149, 464-470.
84. Tahashi Y., Matsuzaki K., Date M. et al. (2002) Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 35, 49-61.
85. Takagawa S., Lakos G., Mori Y., Yamamoto T., Nishioka K., Varga J. (2003) Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J. Invest. Dermatol. 121, 41-50.
86. Taylor L.M. & Khachigian L.M. (2000) Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads. J. Biol. Chem. 275, 16709-16716.
87. Terada Y., Hanada S., Nakao A., Kuwahara M., Sasaki S., Marumo F. (2002) Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 61, 94-98.
88. Tibbs M.K. (1997) Wound healing following radiation therapy: a review. Radiother. Oncol. 42, 99-106.
89. Verrecchia F., Chu M.L., Mauviel A. (2001) Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 276, 17058-17062.
90. Verrecchia F., Tacheau C., Wagner E.F., Mauviel A. (2003) A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta -driven SMAD3/4-specific gene expression. J. Biol. Chem. 278, 1585-1593.
91. Wakefield L.M. & Roberts A.B. (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12, 22-29.
92. Waldrip W.R., Bikoff E.K., Hoodless P.A., Wrana J.L., Robertson E.J. (1998) Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell 92, 797-808.
93. Wang B., Hao J., Jones S.C., Yee M.S., Roth J.C., Dixon I.M. (2002) Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am. J. Physiol. Heart Circ. Physiol. 282, H1685-H1696.
94. Weinstein M., Yang X., Li C., Xu X., Gotay J., Deng C.X. (1998) Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc. Natl. Acad. Sci. USA. 95, 9378-9383.
95. Wendling J., Marchand A., Mauviel A., Verrecchia F. (2003) 5-fluorouracil blocks transforming growth factor-beta-induced alpha2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol. Pharmacol. 64, 707-713.
96. Werner F., Jain M.K., Feinberg M.W. et al. (2000) Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J. Biol. Chem. 275, 36653-36658.
97. Xavier S., Piek E., Fujii M. et al. (2004) Amelioration of radiation-induced fibrosis: inhibition of TGF-β signaling by halofuginone. J. Biol. Chem. 279, 15167-15176.
98. Yang X., Chen L., Xu X., Li C., Huang C., Deng C.X. (2001) TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol. 153, 35-46.
99. Yang Y.A., Dukhanina O., Tang B. et al. (2002) Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615.
100. Yang X., Letterio J.J., Lechleider R.J. et al. (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18, 1280-1291.
101. Yang Y.C., Piek E., Zavadil J. et al. (2003) Hierarchical model of gene regulation by transforming growth factor-beta. Proc. Natl. Acad. Sci. USA. 100, 10269-10274.
102. Yuan W. & Varga J. (2001) Transforming growth factor-beta repression of matrix metalloproteinase-1 transcription in dermal fibroblasts involves Smad3. J. Biol. Chem. 276, 38502-38510.
103. Zeisberg M., Hanai J., Sugimoto H. et al. (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968.
104. Zhang W., Ou J., Inagaki Y., Greenwel P., Ramirez F. (2000) Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2(I)-collagen (COL1A2) transcription. J. Biol. Chem. 275, 39237-39245.
105. Zhao J., Shi W., Wang Y.L. et al. (2002) Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L585-L593.